BAGSVAERD, Denmark, April 22, 2015 (GLOBE NEWSWIRE) -- At Novo Nordisk's Annual General Meeting on 19 March 2015, it was decided to reduce the company's B share capital from DKK 422,512,800 to DKK 412,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 3079 3450 | amhg@novonordisk.com |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
| Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
| Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
| Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com |
Company announcement No 27 / 2015
Company announcement no 27 / 2015 http://hugin.info/2013/R/1913419/683321.pdf
HUG#1913419